If you're an infusion oncology RN, Rush is looking for you. We're having a virtual hiring event on July 31, and we'd love to meet you. Register here: https://rsh.md/4cVS0t0
Rush University Medical Center’s Post
More Relevant Posts
-
Examine the treatment journey for Multiple Myeloma patients with Kristen T. Peterson, PharmD, BCOP, Myeloma Clinical Oncology Pharmacist at Duke University Health System in our newest Insights video series. Dr. Peterson discusses the specific responsibilities of the pharmacist, the importance of collaboration for medication accessibility, real-world evidence, and more! Experience improved comprehension of trending topics in Multiple Myeloma patient care. Watch the episodes here: https://bit.ly/3Scz5CA
To view or add a comment, sign in
-
From potentially lower reimbursements to more affordable cancer care for patients, the Inflation Reduction Act has a wide variety of implications for oncology providers. Click the link below to learn more. #IRA #Reimbursements #Medicare #CancerCare #VBC
How the Inflation Reduction Act Will Impact Real-World Oncology Research
info.ontada.com
To view or add a comment, sign in
-
Pharmacy Focus: Oncology Edition- Integrating Oncology Pharmacists into Multidisciplinary Care Teams for Improved Patient Outcomes: The podcast discusses how City of Hope Chicago fully integrates oncology pharmacists into care teams by positioning them in clinics, improving communication and collaboration to minimize delays for patients and enhance care delivery. #finance #pharmacy #lifesciences
Pharmacy Focus: Oncology Edition- Integrating Oncology Pharmacists into Multidisciplinary Care Teams for Improved Patient Outcomes
pharmacytimes.com
To view or add a comment, sign in
-
How the Patient Perspective Can Drive Powerful Clinical Study Designs in Oncology https://buff.ly/417Mq1A #clinicalstudy #patientexperience #electronicpatientreportedoutcomes #ePROs #clinicaltrials #clinicaldevelopment
To view or add a comment, sign in
-
Streamlining integrated AI-driven tools for advanced oncology care. Elevate your practice with precision and efficiency. . . #AIinOncology #AdvancedCare #HealthcareBalance #PracticeExcellence #HealthcareBalance #PracticeExcellence #ModernHealthcare #PatientCareFirst #healthcaremanagementsoftware
To view or add a comment, sign in
-
We’re excited to share today updated preliminary clinical data from the Phase 1 portion of our ongoing StrateGIST 1 study of IDRX-42 in patients with advanced gastrointestinal stromal tumors, or #GIST, at the American Society of Clinical Oncology (ASCO)’s Annual Meeting. Encouraging signs of clinical activity were observed, including a 23% objective response rate across all patients in a heavily pretreated patient population, and a 43% objective response rate across second-line patients. A favorable tolerability profile was also observed. “In this dataset, IDRx has presented preliminary proof-of-concept of IDRX-42 supporting its potentially best-in-class profile in patients with GIST,” said Tim Clackson, Ph.D., Chief Executive Officer of IDRx. “Importantly, we believe these efficacy and safety data support our plan to move IDRX-42 rapidly into early lines of therapy, including second-line and front-line, where patients haven’t seen a new treatment option in over 15 years.” Read more: https://lnkd.in/ePCh693j Discover more during our oral presentation at #ASCO24: https://lnkd.in/eiPSyZ9f
To view or add a comment, sign in
-
ONCOLOGY MARKETERS AND SALES: Having a hard time getting to oncologists? Imagine if you had access to 57% of all medical oncologists (of 13,365 according to ASCO 2022 State of Oncology), AND imagine that access allowed you to share guidelines-driven educational material or peer-reviewed journal data in the midst of their treatment planning. Oncolens is an oncology treatment planning platform used by more than 200 NCI academic centers, IDNs, and community hospital oncology care teams. Oncolens can help get the right clinical information in the right place at the right time, where it can make a difference for patients, physicians, and life science companies investing in precision medicine. Let's talk!
To view or add a comment, sign in
-
Latest and promising data for IDRX-42 in GIST, just presented at the American Society of Clinical Oncology (ASCO) 2024 meeting. #sarcoma #GIST #ASCO2024
We’re excited to share today updated preliminary clinical data from the Phase 1 portion of our ongoing StrateGIST 1 study of IDRX-42 in patients with advanced gastrointestinal stromal tumors, or #GIST, at the American Society of Clinical Oncology (ASCO)’s Annual Meeting. Encouraging signs of clinical activity were observed, including a 23% objective response rate across all patients in a heavily pretreated patient population, and a 43% objective response rate across second-line patients. A favorable tolerability profile was also observed. “In this dataset, IDRx has presented preliminary proof-of-concept of IDRX-42 supporting its potentially best-in-class profile in patients with GIST,” said Tim Clackson, Ph.D., Chief Executive Officer of IDRx. “Importantly, we believe these efficacy and safety data support our plan to move IDRX-42 rapidly into early lines of therapy, including second-line and front-line, where patients haven’t seen a new treatment option in over 15 years.” Read more: https://lnkd.in/ePCh693j Discover more during our oral presentation at #ASCO24: https://lnkd.in/eiPSyZ9f
To view or add a comment, sign in
-
National Patient Safety Awareness Week takes place from March 10 – 16 each year and aims to highlight the importance of improving safe care throughout healthcare. The theme for 2024 is “Safer Together” which Summit Therapeutics is 100% dedicated to; working with our Clinical Trial Contract Manufacturing Organizations and Clinical Trial Sites to ensure the safety of patients. Summit is focused on resolving serious, unmet medical needs in oncology for the betterment of overall human health, and we do this with an uncompromising insistence on patient safety at every stage of development of our potential oncological treatments. Learn more here: https://lnkd.in/exiXMXXw @ptsafetyexpert @ptsafetyEMS #PSAW24 #PatientSafety #SummitTherapeutics #Oncology #Ivonescimab
To view or add a comment, sign in
-
Interesting publication....how to advance Oncology Care Delivery and Payment Reform....check it out
To view or add a comment, sign in
104,185 followers